ELUT
ELUTIA INC.
NASDAQ · Healthcare · Biotechnology · US
$0.81
−3.13%Year over year
Reported trailing growth
- Revenue
- -48.8%
- EBITDA
- -72.3%
- EBIT
- +35.4%
- EPS
- +236.9%
- Free cash flow
- -34.4%
- Operating cash flow
- -34.2%
Forward estimates
Based on analyst estimates
- Revenue
- -91.8%
- EBITDA
- +77.8%
- EPS
- —
Three-year CAGR
- Revenue
- -19.8%
- EBITDA
- +72.1%
- EBIT
- +48.4%
- Net income
- +198.9%
- EPS
- +169.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026